Objective: To study the improvement of metabolic control and patients satisfaction with glucose continuous monitoring systems (Guardian real time).
Material and method: Fifteen DM1 patients studied (age: 33.8±13.40, years of evolution: 17.06±11.32) in intensive treatment (5 multidoses, 10 insulin pump) which were made one 4 days long blind monitoring Period 1 (blind period) with sensor CGMS Gold. Next another monitoring was made with a real time system with alarms of hyperglycemia and hypoglycemia, Guardian RT, Period 2 (real time period). These 2 monitorings were consecutive in each patient, establishing in the second period the levels of alarm of hypoglycemia in 50 mg/dl and hyperglycemia in 200 mg/dl. We studied in both periods: average glycemia, glycemia variability, percentage of time in hyperglycemia (>180), normal glycemia and hypoglycemia (<70). A satisfaction questionnaire about the systems of continuous monitoring was made.
|Period 1 (blind)||Period 2 (R.T)||P|
|Average glyc||157.17±34.30 (110224)||137.49±21.99 (115203)||0.053|
|Variability||73.72±19.60 (38103)||48.23±13.20 (2575)||<0.005|
|% High||32.56±19.25 (7.075.0)||19.90±13.87 (1.2356.03)||<0.05|
|% Euglycemia||55.49±17.79 (25.086.0)||74.98±14.22 (43.9798.77)||<0.005|
|% Low||11.94±8.04 (0.0029.00)||5.10±5.16 (017.00)||<0.005|
Conclusions: We observed during the monitoring in real time:
Longer time in normal glycemia with less frequency of hypoglycemia and hyperglycemia.
Smaller glycemia variability.
The monitoring in real time could be useful tool at the time of assuring a better metabolic control and to diminish the exhibition to hypoglycemias.
GURADIAN RT did not generate greater anxiety than the GCMS interfering to a lesser extent in the daily life of our patients.
03 - 07 May 2008
European Society of Endocrinology